| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 68,658 | 51,607 |
| Proceeds from exercise of stock options | 203 | - |
| Proceeds from issuance of common stock under employee stock purchase plan | 68 | 68 |
| Net cash provided by financing activities | 271 | 68 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 284 | 361 |
| Net increase in cash, cash equivalents and restricted cash | 4,710 | 5,041 |
| Cash and cash equivalents at beginning of period | 28,235 | - |
| Cash and cash equivalents at end of period | 32,945 | - |
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc. (VTYX)